Volume 9; Issue 3

Main
Targeted Oncology
Volume 9; Issue 3

Targeted Oncology

Volume 9; Issue 3

1

A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma

Waldron, Nate N., Barsky, Sanford H., Dougherty, Phillip R., Vallera, Daniel A.

Journal:

Targeted Oncology

Year:

2014

Language:

english

File:

PDF, 934 KB

english, 2014

2

Recombinant TIMP-1-GPI inhibits growth of fibrosarcoma and enhances tumor sensitivity to doxorubicin

Q. Bao, H. Niess, R. Djafarzadeh, Y. Zhao, B. Schwarz, M. K. Angele, K.-W. Jauch, P. J. Nelson, C. J. Bruns

Journal:

Targeted Oncology

Year:

2014

Language:

english

File:

PDF, 792 KB

english, 2014

3

In vitro induction of potent tumor-specific cytotoxic T lymphocytes using TLR agonist-activated AML-DC

Maryam Nourizadeh, Farimah Masoumi, Ali Memarian, Kamran Alimoghaddam…

Journal:

Targeted Oncology

Year:

2014

Language:

english

File:

PDF, 632 KB

english, 2014

4

Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis

Benjamin A. Gartrell, Jian Ying, Shanthi Sivendran, Kenneth M. Boucher…

Journal:

Targeted Oncology

Year:

2014

Language:

english

File:

PDF, 265 KB

english, 2014

5

A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors

M. Mita, M. Gordon, N. Rejeb, A. Gianella-Borradori, V. Jego, A. Mita…

Journal:

Targeted Oncology

Year:

2014

Language:

english

File:

PDF, 330 KB

english, 2014

6

Curcumin induces apoptosis of HepG2 cells via inhibiting fatty acid synthase

Huijin Fan, Weixi Tian, Xiaofeng Ma

Journal:

Targeted Oncology

Year:

2014

Language:

english

File:

PDF, 554 KB

english, 2014

7

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan

Fotios Loupakis, Chiara Cremolini, Anna Fioravanti, Paola Orlandi…

Journal:

Targeted Oncology

Year:

2014

Language:

english

File:

PDF, 320 KB

english, 2014

8

Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial

Penel, Nicolas, Ray-Coquard, Isabelle, Bal-Mahieu, Christine, Chevreau, Christine, Cesne, Axel, Italiano, Antoine, Bompas, Emmanuelle, Clisant, Stéphanie, Baldeyrou, Brigitte, Lansiaux, Amélie, Robin,

Journal:

Targeted Oncology

Year:

2014

Language:

english

File:

PDF, 251 KB

english, 2014

9

Anti-Sp17 monoclonal antibody–doxorubicin conjugates as molecularly targeted chemotherapy for ovarian carcinoma

Song, Jia-Xi, Li, Fang-Qiu, Cao, Wang-Li, Jia, Xuan, Shi, Li-Ning, Lu, Jing-Fen, Ma, Chun-Fang, Kong, Qian-Qian

Journal:

Targeted Oncology

Year:

2014

Language:

english

File:

PDF, 662 KB

english, 2014

10

Diagnostic challenges of respiratory adverse events during everolimus treatment

Willemsen, Annelieke E. C. A. B., Vos, Filip Y., Jansen, Anne, Boer, Maaike, Tjan-Heijnen, Vivianne C. G., Herpen, Carla M. L.

Journal:

Targeted Oncology

Year:

2014

Language:

english

File:

PDF, 433 KB

english, 2014

11

New agents in renal cell carcinoma

Raetasha Dabney,Ryan Devine,Nancy Sein,Benjamin George

Journal:

Targeted Oncology

Year:

2014

Language:

english

File:

PDF, 260 KB

english, 2014